This Cancer Drug Is Already Working. Now Its Nvidia-Backed Maker Is Going Public: Here’s What You Need to Know About Its IPO

Another Nvidia (NVDA)-backed company is on its way to the stock market. Iambic Therapeutics, an AI-driven drug discovery firm, has filed to go public on the Nasdaq under the ticker IAM. Renaissance Capital estimates the IPO could raise up to $100 million. The Nvidia name will draw attention, but the real question is whether the company underneath is worth owning.

What Iambic Actually Does